Delivering our partners preclinical discoveries through world class capabilities,
directed by teams with a reputation for collaboration and scientific excellence
Insights from target to IND
Cutting-edge synthetic technology and expertise in special chemical matters have been centralized to form a variety of special chemistry platforms.
Magical Power of QM
To Empower Organic Syntheses
With powerful workstations, state of the art software, and our expertise on reaction QM analyses, real-time incorporations of such calculations in prospective analyses become routines in Research Service Division.
A Diverse New Modality That Unlocks New Target Classes
Bifuctional molecules are opening up once-inaccessible targets and enabling development of drugs that are less susceptible to target protein mutations.
CRISPR Library Screen
A Powerful Tool For Identifying Novel Tumor Targets
Cancer is a genetic disease. Over time, somatic mutations accumulate and drive the proliferation of tumor cells. Knowledge of that process has spurred systematic efforts to identify genes essential to the survival of different cancer cells.
Enabling Technology for Targeted Protein Degradation
Identification and characterization of new bifunctional molecules including degraders using synergistic power of fragment and DEL screening, biophysics and structural biology
Partner of ‘Target-to-Hit’ discovery
WuXi AppTec HitS Unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. As an innovation-driven and customer-focused unit, HitS helps our partners to improve the productivity of advancing hit discovery through high-quality and cost-effective solutions. With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structure-based drug design, HitS is committed to drive toward the realization of the vision that every drug can be made and every disease can be treated.